Fig 2: Kaplan-Meier survival plots for overall survival in TCGA ccRCC cohort(A–H) For 8 genes (SCG5, SPOCD1, RGS19, SH2D5, PGF, ARHGAP22, EVI2A, and TGM2), overall survival was significantly reduced in patients with high mRNA expression in comparison with that in patients with low expression in ccRCC. (I–L) Cox proportional analysis showed that SCG5, SPOCD1, RGS19, and ARHGAP22 were independent predictors of overall survival in ccRCC.

Fig 3: Effects of JQ1 treatment on the expression of SCG5, SPOCD1, RGS19, and ARHGAP22 mRNAs in 786-o and SU-R-786-o cells(A–D) qRT-PCR demonstrated that SCG5, SPOCD1, RGS19, and ARHGAP22 were significantly upregulated in SU-R-786-o cells compared with those in 786-o cells and downregulated by JQ1 treatment (2.5 μM) in 786-o and SU-R-786-o cells. GUSB was used as an internal control.

Fig 4: BRD4 bound to the promoter regions of SCG5, SPOCD1, RGS19, and ARHGAP22 genesChIP assays were performed using normal rabbit IgG or anti-BRD4 antibodies as described in the Materials and Methods. We found that BRD4 was highly enriched at promoter regions of SCG5, SPOCD1, RGS19, and ARHGAP22 in SU-R-786-o cells.